B

Baroness Merron (Lab)

Speaking in the House of Lords on 9 November 2026

Debate

Health Bill

Contribution

My Lords, I am most grateful for the constructive amendments that have been tabled on cancer services. Noble Lords will know that we take this issue very seriously, as evidenced by our national cancer plan, which sets out very clear priorities to transform cancer care and outcomes over the next 10 years. In addition to that, I say to the noble Lord, Lord Evans, that what is being spoken about now strikes at the very core of the Health Bill and the reasons we are taking the actions that we are to be able to improve the situation still further. I recognise the impact of cancer on many noble Lords, either directly or indirectly, and I thank them for bringing their personal experience to the debate. It is important not just within this Chamber but to so many people outside, where one in two will be affected by cancer. I will address some of the amendments before us. On Amendment 41, I can assure the noble Baroness, Lady Pidgeon, of our commitment to improving cancer outcomes. The noble Lord, Lord Stevens, welcomed our national cancer plan, which sets out an ambition to increase five-year survival to 75% by 2035, which will save an estimated 320,000 more lives over the next decade. The current law requires the NHS mandate to include cancer outcome objectives, which NHS England must prioritise over other cancer-specific objectives. With the abolition of NHS England that mechanism will no longer be needed, but that is because our focus on prioritising cancer outcomes remains. I hope that that is the start of a reassurance to my noble friend Lady Morgan, who raised this point, and rightly so, at Second Reading. The plan provides a clear programme for delivery, supported by annual reporting on progress against key measures and targets. Last month, we confirmed a new independent National Cancer Board that will help scrutinise our progress—progress that the noble Lord, Lord Patel, rightly seeks—and, importantly, will ensure that the voice of cancer patients is heard. I know my noble friend Lady Ritchie will particularly welcome that. We therefore consider an additional statutory duty to prioritise cancer outcome objectives unnecessary, in terms of legislation. Our priority, as the noble Lord, Lord Patel, spoke to, is to deliver the commitments of the plan. Amendment 217 addresses research into cancers with the lowest survival rate. We invest around £1.8 billion each year on research through the National Institute for Health and Care Research. Cancer is a major area of expenditure, standing at £141.6 million in 2024-25, which reflects its high priority. We recognise that research into all cancers—a point that a number of noble Lords have raised—including those with the lowest survival rate, is a key priority. Research is funded through open competition and peer review to ensure that the highest-quality proposals—the ones that are most likely to deliver real impact for patients—are funded without imposing financial targets or limits. Our cancer plan includes a commitment to make progress on rare cancers one of the six key research priorities, to tackle stubbornly low survival rates. Our aim is to be in the top quartile across 28 countries for survival of 14 rare and less common cancers. To the point made by my noble friend Lady Nargund, we are strengthening international research collaboration. For example, a joint call with the Japan Agency for Medical Research and Development opened just last month, to which the NIHR is committing a total of £2 million to support UK-based components. In respect of my noble friend’s question about pathways from MHRA and NICE trials to making treatments available, this is absolutely key. A new cancer trials accelerator will make the NHS the first-choice partner for cancer clinical trials. I can confirm to the noble Baroness, Lady Finlay, that the DHSC still participates in and influences the EU cancer mission. I hope that noble Lords will appreciate that we very much see the importance of international work, both with our EU partners and beyond the EU. My noble friend Lady Morgan seeks reassurance that there will be an appropriate and dynamic focus on improving participation in clinical trials. The answer to that is yes. We are also looking into options to contact patients with rare cancers to offer them the opportunity to be part of clinical trials, through a tailored version of the Be Part of Research service. My noble friend will also know the demanding targets we have set ourselves in terms of setting up clinical trials. Turning to Amendment 228, improving performance against cancer waiting standards is absolutely key. There has been year on year progress with waiting times, but I would be the first to admit that there is some way to go. To my noble friend Lady Royall, as well as the noble Lord, Lord Evans, I can say that cancer waiting time targets, including the 62-day referral to treatment target, are not set at 100% for several reasons. They include patient choice, clinical guidelines and the reality and complexity of diagnosis and treatment planning, which mean that not every patient can or should be treated within the waiting time standard. Change, including improvements to parts of the cancer pathway and tackling variation in performance across trusts, which is something I know is of concern to noble Lords, will not be delivered overnight, but the national cancer plan sets out the concrete and measurable actions in how we are going to get there. I assure the Committee that the plan makes a clear commitment to meet all the cancer waiting time standards. We will go further, reviewing them once they have been met, to consider whether they should be strengthened. In other words, it will not be case of job done and move on; we will review what more we can do. I am grateful to my noble friend, Lady Royall, for bringing Amendment 233 before the Committee today. The Government are determined to improve outcomes for men with prostate cancer, and we have partnered with Prostate Cancer UK on the £60 million TRANSFORM trial to find the best way to screen men for prostate cancer. That was something the noble Lord, Lord Evans, raised. However, as noble Lords will be aware, the case for an early detection programme has recently been considered through the UK National Screening Committee’s established evidence review process. For men without symptoms, early detection would, in practice, amount to screening. The committee therefore recommended screening only where the evidence shows that the benefits outweigh the harms. With prostate cancer, earlier detection is not always better. Many prostate cancers are slow growing and may never cause harm, while PSA testing cannot reliably distinguish these from aggressive cancers. Screening can therefore sometimes lead to overdiagnosis and unnecessary treatment, with potentially life-changing consequences, so we continue to be guided by the evidence. My noble friend Lady Royall also asked about further inclusion. Prostate Cancer UK is using local government engagement grants to ensure that local organisations that work in Black communities can support recruitment to the trial, which was the point she was concerned about, and can also spread awareness of the trial. Turning to Amendments 247 and 250, tabled by the noble Baroness, Lady Finlay, the Government agree that genomic testing should be timely, equitable and fully integrated into cancer care. The cancer plan commits to providing genomic testing to every cancer patient who would benefit from one within a clinically relevant timeframe, so that the results can inform treatment decisions. Our focus is on ensuring that the NHS Genomic Medicine Service works consistently for patients and ensures that results inform treatment. To the point about workforce, we will create 5,000 learning and training opportunities each year, including opportunities to develop knowledge of emerging technologies, such as genomics. At the same time, NHS England is improving the links between pathology and genomics, expanding molecular profiling and developing national digital arrangements for requesting and tracking tests. These improvements are best taken forward through NHS commissioning and service arrangements, in our view, rather than through a broad statutory duty, so there can be adaption as clinical evidence and technology develops. I was glad to hear the noble Lord, Lord Patel, welcome the establishment of the genomic hubs and the work they do. Finally, I turn to Amendment 250. We share the ambition in terms of radiotherapy, and patients should have timely access to modern, effective treatment wherever they live. The noble Lord, Lord Tarassenko, spoke to the points on radiotherapy. However, it is our view that a specific duty for the Secretary of State for one treatment in particular would set a precedent and cut across the devolved models in which local systems and cancer alliances are expected to deliver.

More from Baroness Merron (Lab)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.